Prometheus releases trio of tissue-specific microRNA tests

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Prometheus Laboratories has launched the ProOncDx line of cancer diagnostic tests. ProOncDx TumorSource pinpoints the tissue of origin in metastatic tumors in a number of cancers including breast, brain, kidney, colon, liver, ovary, lung, pancreas, and prostate. The test measures the expression level of 48 microRNA biomarkers

Prometheus Laboratories has launched the ProOncDx line of cancer diagnostic tests. ProOncDx TumorSource pinpoints the tissue of origin in metastatic tumors in a number of cancers including breast, brain, kidney, colon, liver, ovary, lung, pancreas, and prostate. The test measures the expression level of 48 microRNA biomarkers.

ProOnc SquamousDx differentiates between squamous histology and non-squamous histology in non-small-cell lung cancer.

Finally, ProOnc MesotheliomaDx differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content